Biomerica (NASDAQ:BMRA – Get Free Report) and Cytosorbents (NASDAQ:CTSO – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation.
Volatility and Risk
Biomerica has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings for Biomerica and Cytosorbents, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biomerica | 1 | 0 | 0 | 0 | 1.00 |
| Cytosorbents | 1 | 1 | 1 | 0 | 2.00 |
Earnings & Valuation
This table compares Biomerica and Cytosorbents”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biomerica | $4.45 million | 1.56 | -$3.78 million | ($1.27) | -1.76 |
| Cytosorbents | $37.06 million | 0.54 | -$8.20 million | ($5.80) | -1.11 |
Biomerica has higher earnings, but lower revenue than Cytosorbents. Biomerica is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Biomerica and Cytosorbents’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biomerica | -84.79% | -97.19% | -61.57% |
| Cytosorbents | -48.94% | -431.65% | -41.94% |
Insider and Institutional Ownership
22.3% of Biomerica shares are owned by institutional investors. Comparatively, 32.9% of Cytosorbents shares are owned by institutional investors. 18.0% of Biomerica shares are owned by company insiders. Comparatively, 7.8% of Cytosorbents shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Cytosorbents beats Biomerica on 9 of the 14 factors compared between the two stocks.
About Biomerica
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
About Cytosorbents
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.
